IN THE CLAIMS:

Claims 1-20 (Cancelled)

21 (New). A compound for use in inducing necrosis in vascular tissue of a tumor in an animal, said compound containing (a) a first moiety which is a cis-stilbene moiety of formula II



II

Wherein

R1, R2 and R3 are each independently H, optionally substituted alkoxy, optionally substituted alkyl or halogen

R4 is hydrogen or cyano

R5, R6 and R7 are each independently H, hydroxy, optionally substituted alkoxy, optionally substituted alkyl, halogen, amino, alkylamino, dialkylamino, cyano, nitro, carboxyl, alkanoyl, alkoxycarbonyl, alkoxycarbonyloxy, alkoxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, alkylcarbonylamino, alkylsulphonyl, aminosulphonyl, alkylaminosulphonyl, dialkylaminosulphonyl, alkylsulphonylamino, aminosulphonylamino, alkylaminosulphonylamino, dialkylaminosulphonylamino, mercapto, alkylsulphanyl or alkylsulphinyl,

with the proviso that at least two of R1, R2 and R3 must be optionally substituted alkoxy,

and (b) a second moiety which is an inhibitor of the formation or action of nitric acid, said first and second moieties being coupled in the compound such that the compound has an increased activity in inducing necrosis in said vascular tissue as compared with a compound containing said first moiety without the second moiety.

22 (New). The compound according to claim 21, wherein the second moiety is an inhibitor of nitric oxide synthase.

23 (New). The compound according to claim 22, wherein the compound is a hydrate, a pharmaceutically acceptable salt or a prodrug.

24 (New). The compound according to claim 22, wherein the first and second moieties are coupled through a linker bond, atom or group.

25 (New) The compound according to claim 22, in which the first and second moieties are coupled through a linker group selected from the group consisting of an optionally substituted methylene chain, and $-(CH_2)_m-Y-(CH_2)_n-$ wherein Y is selected from -O-, -S-, SO_2-, NH-, Nalkyl-, -CO-, -OC(O)-, -NHC(O)-, -N(alkyl)C(O)-, -NHC(O)NH-, NalkylC(O)NH- NalkylC(O)Nalkyl-, $-NHSO_2-$, $NalkylSO_2-$, $NHSO_2NH-$, $NalkylSO_2NH-$, $NalkylSO_2Nalkyl-$ and -OC(O)O-, m is 0-3 and n is 0-3.

26 (New) The compound according to claim 22, in which the second moiety is selected from the group consisting of an amino acid inhibitor of nitric oxide synthase,

a tiocitrulline derivative, an S-alkylisothiourea derivative and 2-aminopyridine derivative.

Claim 27 (New) The compound according to claim 22, wherein the second moiety is a group -C(O)CH(NH_2)-CH_2)p-NHC(NH)Z wherein p is 1-5 and Z is alkyl, alkylamino, dialkylamino, nitroamino, hydrazino or alkylthio, or a group -NHCH(CO_2R10)-(CH_2)p-NHC(NH)Z and R10 is hydrogen or alkyl.

Claim 28 (New) The compound according to claim 22, wherein the second moiety is a group -C(O)CH(NH_2)-CH_2p-NHC(S)NH_2 or a group -NHCH(CO_2R10)-(CH_2)p-NHC(S)NH_2.

Claim 29 (New) The compound according to claim 22, wherein the second moiety is -(CH_2)p-SC(NH)NH_2.

Claim 30 (New) The compound according to claim 22, wherein the second moiety is 4-methyl-2-pyridinylamino.

Claim 31 (New) The compound according to claim 22, wherein the compound is



III

wherein B is the second moiety; X is a linker bond, atom or group; and R8 is alkyl, amino, hydroxy, alkoxy or halogen.

Claim 32 (New) The compound according to claim 31, wherein X is -O- or -NH- and B is a group -C(O)CH(NH_2)-(CH_2)p-NHC(NH)Z, wherein p is 1-5 and Z is alkyl, alkylamino, dialkylamino, nitroamino, hydrazino or alkylthio or a group -NHCH(CO_2R10)-CH_2)p-NHC(NH)Z and wherein R10 is hydrogen or alkyl.

Claim 33 (New) The compound according to claim 32, wherein the compound is



IV

wherein

R9 is alkyl, alkoxy or halogen

X_1 is O or NH

B_1 is a group -C(O)CH(NH_2)p-NHC(NH)Z wherein p is 1-5 and Z is alkyl, alkylamino, dialkylamino, nitroamino, hydrazino or alkylthio.

34 (New) The compound according to claim 22, wherein the compound is selected from the group consisting of

(Z)-1-(4-Methoxy-3-N^G-nitroarginyloxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene

(Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenoxycarbonyl]N^G-nitroarginine methyl ester;

(Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenoxycarbonyl]N^G-nitroarginine; and

(Z)-N-[2-methyl-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenoxycarbonyl]N^G-nitroarginine methyl ester.

35 (New) The compound according to claim 22, wherein the first and second moieties are coupled through a linker bond.

36 (New). A method for inducing necrosis in vasculature of a tumor in an animal, comprising administering to the animal the compound of claim 34 in an amount effective for said inducing.

37 (New). A method for inducing necrosis in vasculature of a tumor in an animal, comprising administering to the animal the compound of claim 22 in an amount effective for said inducing.

38 (New). A method for inducing necrosis in vasculature of a tumor in an animal, comprising administering to the animal the compound of claim 24 in an amount effective for said inducing.

39 (New). A method for inducing necrosis in vasculature of a tumor in an animal,

comprising administering to the animal the compound of claim 27 in an amount effective for said inducing.

40 (New). A method for inducing necrosis in vasculature of a tumor in an animal, comprising administering to the animal the compound of claim 31 in an amount effective for said inducing.